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Objectives: Comprehensive long-term outcome data after endovascular aneurysm repair (EVAR) are scarce, although
anecdotes of endograft failure in the early 1990s abound. The objective of this report is to provide comprehensive
outcomes after EVAR performed with the earliest available endograft components. These were a home-made endograft
(pre-expanded polytetrafluoroethylene [PTFE] fixed with giant Palmaz stents) and first-generation Talent endografts
(World Medical, Sunrise, Fla).
Methods: A prospectively recorded database of all cases undertaken at a tertiary referral center was retrospectively
interrogated. Sex, age, types of endograft used, and fate of patient and endografts implanted between 10 and 15 years
previously were studied. A literature search was undertaken to obtain data for long-term survival after EVAR and open
surgery (OR).
Results: There were 50 patients in total operated on between 1994 and 1998 of whom 43 were male. The median age was
73 years (54-93) at time of EVAR and 85 years (67-100) in the survivors at a median of 12 years later. There were 26
home-made (PTFE fixed with Palmaz stents) and 24 Talent endografts (World Medical). Thirty-day mortality was 4%,
one death in a ruptured abdominal aortic aneurysm. Twenty-one (42%) survived for 12 years to the time of reporting. Of
these, 6 have functioning home-made endografts, 8 have Talent endografts, and 8 (5 home-made and 3 Talent) survive
after conversion to OR. Secondary interventions took place in 9 further patients. Of 27 late deaths, 1 suffered endograft
sepsis, 20 died of cardio-respiratory causes and 6 died of cancer. The only report of more than a 10-year survival after OR
was found in an e-publication from Sweden. The projected survival after 10 years was 40% for unruptured aneurysms.
However, survival in the general population was higher at 60%.
Conclusions: Ten-year survival after EVAR parallels that of elective OR but is less than the general population. Although
the rate of eventual conversion to open repair was high using this earliest available endograft technology, the
aneurysm-related mortality was low, and both endografts remain functional for more than 10 years after placement.
(J Vasc Surg 2010;52:49-54.)Juan Parodi1 first described endovascular aneurysm
repair (EVAR) using a Dacron prosthetic tube endograft
fixed with Gianturco stents in an aorto-aortic configura-
tion. After some years, the aorto-aortic reconstruction gave
way to an aorto-monoiliac configuration owing to the
instability of the former at the distal aortic end. Following
this, Chuter2 described the aorto-bi-iliac reconstruction
employing a uni-body home-made prosthesis. Meanwhile,
ClaudeMiahle3 introduced the modernmodular two-piece
device requiring cannulation of the short or stubby limb via
the contralateral iliac artery.
Pre-expanded polytetrafluoroethylene (PTFE) fixed
with “giant” Palmaz stents was described by Bray4 again in
an aorto-aortic configuration. Veith5 used pre-expanded
PTFE with fixation at the aortic neck and femoral artery
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doi:10.1016/j.jvs.2010.02.257with Palmaz stents. Bell6 devised a semi-endovascular
approach using pre-expanded PTFE and a complex sys-
tem with a Dacron trouser prosthesis and four separate
anastomoses with eventual fixation in the femoral artery.
This unit in company with Bergeron in Marseilles and
Bray in Newcastle, Australia7,8 developed the original
Bray technique using pre-expanded PTFE and Palmaz
stent fixation as an aorto-uni-iliac (A-U-I) reconstruc-
tion with the lower landing site in the common iliac
artery. All monolilac reconstructions necessitated occlu-
sion of the contralateral iliac artery and a cross-femoral
bypass.
The earliest manufactured endografts were devel-
oped by Mintec, Inc, Nassau, Bahamas9 as a modular
bi-iliac device based on Miahle’s work, and Endovascular
Technology (EVT; Boston Scientific Boston, Mass)
commercialised Chuter’s idea of the unibody device.10
These early manufactured devices failed in the short term
because of weak fabric and stents in the case of Mintec,
and, partially because of twisting and kinking of the iliac
limbs in the case of EVT, which was withdrawn by the
manufacturer for legal and regulatory reasons.
The first home-made endograft employed in London
and the first Talent (World Medical/Medtronic Inc, Los
49
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deployed in this unit.
The literature contains several case series with immedi-
ate or short-term follow-up after EVAR of infrarenal ab-
dominal aortic aneurysms (AAAs). OR has not been sub-
jected to detailed scrutiny during early and late follow-up in
the way EVAR has.11
Few reports of these early attempts at EVAR during the
early-mid 1990s exist. The conversion rate from large reg-
istries is 1% to 5% per annum,11 and the AAA rupture rate is
1% per annum.11
The objective of this report is to describe long-term
outcomes in a cohort of patients treated for infrarenal AAAs
with the earliest available endograft technology. Specifi-
cally, survival rates of conversion to open repair (OR) and
aneurysm-related mortality were investigated.
PATIENTS AND METHODS
A prospectively recorded database of all cases of EVAR
from 1994 to 1998 was interrogated. Age, sex, and en-
dograft type were noted, as was early and late mortality and
cause of death. Conversions and their timing as well as
secondary interventions during the 12 years of follow-up
were recorded.
Such data, and in particular, survival, cause of death,
aneurysm-related mortality, and graft-related complica-
tions were recorded prospectively in the database. Fol-
low-up was 6monthly for the first 4 years and then annually
by patient consult/interview. Imaging was by three-dimen-
sional (3-D) computed tomography (CT) for the first 3
years at annual intervals, and 6 monthly by Duplex ultra-
sound and plain abdominal X-ray. Preliminary aortic neck
length and diameters were recorded and are here reported.
Aneurysm diameter was noted at each visit, and the prelim-
inary and final diameter at the last visit in survivors is
reported here.
Preoperative imaging was by 3-D CT scanning. En-
dograft planning and linear and volumetric measurement
was by multiplanar reformatting and 3-D reconstruction
with the central flow line as reference.12 The technology
was developed in this unit.
Statistical methods were employed using Stata 10 soft-
ware package for the Kaplan-Meier estimates and the 2 test
for difference between populations.
RESULTS
Forty-three males and 7 females with a median age of
73 years (range, 54-73 years) underwent EVAR over the
defined period. Complete data to 10 years of follow-up
were available on all 50 patients, and in 26, after 12 years
from surgery. Median age of the cohort at the end of the
study was 85 years (range, 67-100 years).
The first 26 patients were selected from patients re-
jected by our and other units for open surgery as being
judged to be too high risk for that approach. All these
underwent EVAR using the home-made device. The sub-
sequent 24 cases reported here all underwent EVAR by the
Talent endograft.The neck diameter was 25 cmmedian (21-27 cm). The
neck length was 26 cm median (12-30 cm). AAA sac
diameters were 5.8 cmmedian (5.1-7.1 cm) preoperatively.
Neck angulation was 60°.
The type and configurations of EVAR are shown
in Table I. After the (first) 11 aorto-aortic home-made
EVAR deployments, this configuration was abandoned in
favor of A-U-I and aorto-bi-iliac (A-B-I) configurations.
Home-made endografts were fabricated in the operating
room just prior to surgery (Figs 1 and 2). Completion
angiogram is shown in Fig 3.
Details concerning conversions are summarized in Ta-
ble II. Two aorto-aortic deployments were converted 30
days and 9  30 days for lower-end endoleakage. One
A-U-I (home-made) was converted at 18/12 postopera-
tively for graft sepsis. Three Talent endografts were con-
verted 30 days: two A-U-I for occlusion and one for
upper-end type1 endoleakage (All aorto-aortic endografts
failed in the long or short term and required conversion
Table II).
At completion of the study, it was noted that in all
surviving Talent endografts, the sac thrombus reduced or
disappeared with sac shrinkage. However, in the home-
made group, the sac diameter and thrombus volume
showed no significant change from the preoperative level.
Mortality within 30 days of surgery and later is shown
in Table III. There were two cases of 30-day mortality:
one after a ruptured EVAR and one after conversion to
open surgery in the home-made group. The patient who
died of a rupture presented with a contained rupture. The
sac diameter was 5.1 cm. A home-made endograft deploy-
ment was attempted but failed. He died the day after
conversion to OR. No case of sac rupture was observed
after successful endograft deployment. The two deaths
represent a 4% incidence of aneurysm-related death.
Of the 27 late deaths, 1 suffered endograft sepsis, 20
died of cardio-respiratory causes, and 6 died of cancer 3
months to 9 years after surgery. Kaplan-Meier curves of
survival of the whole group and of the home-made and
Talent subsets are shown in Figs 3 and 4.
Secondary intervention was required in nine other pa-
tients (Table IV). In five home-made EVARs, three re-
quired extension to the external iliac artery after develop-
ment of a lower landing site aneurysm 5 to 8 years
postoperatively. Two home-made EVARs required inser-
tion of wall stents to overcome mid-graft kink. Two Talent
EVARs required upper-end cuff extensions for type 1 en-
Table I. Endograft configuration and distribution of
home-made and Talent endografts
Endograft
configuration
Home-made
endografts
Talent
endografts
Aorto-aortic 11 0
Aorto-uni-iliac 15 4
Aorto-bi-iliac 0 20doleakage 2 and 3 years postoperatively. One patient with
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unilateral endograft limb occlusion.
DISCUSSION
This study demonstrates that with standard indications
for elective surgery for AAAs in terms of maximal sac
diameter, the earliest available endograft components
could be employed in the early/mid 1990s. The proviso
being that accepted criteria for neck diameter and length
and neck angulation were met. Conversion rates were high
in the case of the home-made device owing to a lack of
extension cuffs, tube grafts, occluding stents, and other
technology now at the disposal of the endovascular sur-
Fig 1. A, Pre-expanded polytetrafluoroethylene (PTFE
Cook 30-mm-diameter balloon.B, Pre-expanded PTFE s
at the lower iliac landing site (common iliac artery).
Fig 2. Completion angiogram after endovascular aneurysm re-
pair (EVAR) with University CollegeHospital home-made device.
Aorto-uni-iliac with cross-femoral bypass and coil occlusion of
contra-lateral common iliac artery.geon.The early home-made devices when deployed in an
aorto-aortic configuration in infrarenal AAAs invariably
failed early, owing to instability of the lower landing site
due to unfavorable aortic geometry and the forces experi-
enced in aortic blood flow.13 All such cases underwent
conversion by OR. However, A-U-I constructions were
more robust and some survive to the present time. Good
results were noted in this era by several different units, and
the A-U-I configuration appeared more durable.14
In this study, open conversion did have a low mortality
despite the majority of patients being originally regarded as
unfit for open surgery. Similar findings were reported by
e sutured onto a giant Palmaz stent and mounted on a
sutured to a Palmaz stent for fixation ofmain PTFE tube
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50 29 24 9 0
Number at risk
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Kaplan-Meier survival estimate
Months 0 50 100 150
Patients at 
Risk 50 29 24 9
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Fig 3. Kaplan-Meier survival curve of 50 patients undergoing
endovascular aneurysm repair (EVAR) 1994 to 1998. Time on X
axis in months. SE, Standard error.) tub
leeveother early studies.15 Difficulty with criteria for definition
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EVAR II trial16 of EVAR vs best medical treatment in
patients considered unfit for OR. Several patients regarded
as unfit for OR underwent the same with good survival.
Even with the small numbers in this study, the conver-
sion rate to OR appears excessive in the case of the home-
made device. However, this was probably due to the aorto-
aortic configuration that was used exclusively with this
device, all of which failed.
The unchanging sac volume seen in the home-made
Table II. Conversions to open repair and their timing afte
Conversions/no conversions with time in
weeks/years Home-made end
Converted 4 weeks postop 2 aorto-aortic
Converted 4 weeks to 2 years postop 10 (9 aorto-aortic, 1 ao
Not converted 14
Table III. Mortality after EVAR–early and late
Time after surgery Home-made endograf
30 days 2
1 rupture
1 after open conversion on table
30 days to 144 months 13
1 graft sepsis at 18 months
10 cardio-respiratory failure at 2 to
2 cancer at 48 to 76 months
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Graphs by Technique
Kaplan-Meier survival estimates
Homemade    Talent 
Months 0 50 100 150 0 50 100 150
Patients 
at Risk 26 14 13 9 24 15 11 0
SE 0 9.8 9.8 9.8 0 7.1 7.1 7.1
2 = 0.03
P < 0.8
Fig 4. Kaplan-Meier survival curve of home-made vs Talent en-
dografts. Time on X axis in months. SE, Standard error.device was previously described.12 It appears to be a char-acteristic associated with PTFE fabric. It has also been
described with PTFE-manufactured devices. None of the
sacs expanded and there were no ruptures.
Randomized controlled trials of EVAR vs OR have
shown EVAR to have a superior outcome in terms of
immediate and short-term mortality in the patient fit for
OR.17 Since Parodi first demonstrated feasibility of EVAR,
there has been an explosion of this technology that has led
to a reduction in the number of cases undergoing OR.
With balloon-expandable stent fixation, it was widely
expected that the proximal landing site would expand and
endograft migration would result. This was not our expe-
rience and a similar experience has been reported by May
and White in Australia.15 However, we have previously
reported a 3% lower-end type I endoleakage rate after 5 to
6 years with both types of endograft. This endoleak was a
consequence of continuing aneurysmal degeneration at the
lower landing site.19,20 The onset occurred after at least 5
years after EVAR. The need for long-term, and possibly
life-long, endograft surveillance has now been established.
Manufactured devices have improved in terms of dura-
bility, ease of usage, and applicability in the differing and
more challenging geometries of AAAs. The earliest manu-
AR
ts Talent endografts
0
ni-iliac) 3 (1 late upper-end endoleak, 2 late occlusion uniliac)
21
Talent endografts
0
months
14
10 cardio-respiratory failure at 6 to 144 months
4 cancer at 60 to 72 months
Table IV. Secondary intervention after EVAR
Home-made
endografts
Talent
endografts
Endograft extension to external
iliac for late lower-landing site
aneurysm formation 3 2
Insertion wall stent to overcome
mid-graft kink 2 0
Upper end extension with cuff 0 1
Cross-femoral bypass for iliac
limb occlusion 0 1r EV
ograf
rto-uts
144factured devices, which include Stentor (Mintec, Inc),
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and Vanguard (Boston Scientific Corporation, Natick,
Mass) have become obsolete due to endograft failure, (and
to withdrawal by the manufacturer in the case of EVT) in
the medium and long term, or have been withdrawn for
regulatory reasons in the case of EVT. Talent (World
Medical/Medtronic) was developed early and has re-
mained durable since its earliest usage.20
Operative mortality has been shown to be less than 3%
with newer manufactured devices. Our initial experience
was of a mortality of two of 26 with our home-made device
and no mortality when the Talent device was introduced.
The conversion rate to OR was greater early in our experi-
ence and particularly with the home-made device. During
the mid 1990s, endovascular technology was primitive, and
cuffs, collars, and occluding stents were not manufactured.
Because of the newness of the technology, type I endoleak-
age, particularly at the upper landing site, was treated by
immediate or early conversion to OR.
By the late 1990s, better endovascular technology al-
lowed endovascular solutions to problems of early and late
endoleakage, and the conversion rate to OR was reduced.
The secondary intervention rate has remained high to the
present day. This unit has previously reported its secondary
intervention rate,21 which is in keeping with other level I
evidence. An uncommon complication of aneurysmal de-
generation at the lower (common iliac) landing site leading
to sac reperfusion and rupture was reported by this
unit.18,19 The onset occurred after at least 5 years after
EVAR. The need for long-term, and possibly life-long,
endograft surveillance has now been established.
It is anticipated that the newest manufactured devices
will offer durability in excess of 10 years. The median age of
the 42% of patients who survived more than 10 years after
EVARwas 85 years. In the only reported 10-year follow-up
of patients who have undergone OR,22 41% of 8663 pa-
tients survived 10 years. The life expectancy of the normal
population in this study exceeded that in patients undergo-
ing OR and EVAR. It is likely that life expectancy of the
normal population will increase further in this century.
Hence, construction and design of modern endografts will
need to take into account this increased life expectancy and
provide the increased robustness and durability that will be
called for.
A limitation of this study is that the data were prospec-
tively collected in a database but retrospectively analyzed.
The study describes very early experience with the technol-
ogy that was not commonly utilized world-wide. These
endografts here described are no longer available and,
therefore, extrapolation of these results to modern-day
endo-technology and practice is inappropriate.
In conclusion, both endografts continue to function
more than 10 years after implantation. Further, the basic
concepts and the hopes of the pioneers in the field for
safety, feasibility, and efficacy of the technology appear to
have been realized in this study. Finally, the importance of
collaboration and contribution by industry is well illus-
trated by the experience here described.AUTHOR CONTRIBUTIONS
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